Drugs & Targets FDA approves Degevma, a biosimilar for cancer-related bone complications October 02, 2026Vol.52 No.36
Drugs & Targets FDA approves Ponlimsi, a biosimilar for preventing fractures in prostate and breast cancer patients October 02, 2026Vol.52 No.36
Drugs & Targets FDA accepts NDA and grants Priority Review to Lynkuet for vasomotor symptoms due to endocrine therapy in breast cancer October 02, 2026Vol.52 No.36
Drugs & Targets FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma September 25, 2026Vol.52 No.35
Drugs & Targets FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component September 25, 2026Vol.52 No.35
Drugs & Targets FDA grants Priority Review to perioperative IMFINZI + enfortumab vedotin for muscle-invasive bladder cancer September 25, 2026Vol.52 No.35
Drugs & Targets FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer September 18, 2026Vol.52 No.34
Drugs & Targets FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC September 18, 2026Vol.52 No.34
Drugs & Targets FDA grants accelerated approval to iberdomide combination for MM September 11, 2026Vol.52 No.33
Drugs & Targets FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer September 11, 2026Vol.52 No.33
